ALDX

Aldeyra Therapeutics

Fundamental data last updated:March 2, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

-

Business Summary

Aldeyra Therapeutics is a biotechnology company focused on the discovery and development of novel therapies for immune-mediated diseases. Its primary programs target ocular and systemic inflammatory conditions.

 


Analyze ALDX on TradingView

VALUATION

P/E

-

Market Cap ($M USD)

$328

Forward P/E

17.4

PEG

-

PRICE TO SALES

-

PRICE TO BOOK

6.7

EV / EBITDA

5-Year Average P/E

Free Cash Flow Yield

DCF Value

Graham Number

Price to FCF

EV to FCF

Earnings Yield

FCF Yield

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$0.73

Next Year EPS Growth Estimate

$0.31

Next Year Revenue Growth Estimate

33.30%

Return on Equity (ROE)

-87.70%

FREE CASH FLOW

Operating Margin

-

Debt-to-Equity

0.3

Piotroski F-Score

Altman Z-Score

Return on Invested Capital (ROIC)

Current Ratio

Quick Ratio

Net Debt to EBITDA

Interest Coverage

Gross Profit margin

FCF PER SHARE

REVENUE PER SHARE

Analyze ALDX on TradingView

Gainseekers Quantitative Analysis

Summary

With a market cap of $328 million, the company is currently unprofitable, posting an EPS of -$0.73 and a Return on Equity of -87.70%. However, future estimates are positive, with sales growth projected at 33.30% and an estimated EPS of $0.31 for next year. The company maintains a low debt-to-equity ratio of 0.3 and has significant institutional ownership at 65.80%.

AI Exposure / Tech Reliance

The provided financial data does not contain specific metrics regarding the company's AI exposure or technological reliance.

The Bull Case

The bull case is supported by a strong consensus rating of 1.33 and a mean target price of $9.00, with analysts forecasting 33.30% sales growth next year. Furthermore, the company is expected to achieve profitability with an estimated EPS of $0.31 next year while maintaining a low debt-to-equity ratio of 0.3.

The Bear Case

The bear case centers on current unprofitability, evidenced by an EPS of -$0.73 and a deeply negative Return on Equity of -87.70%. This skepticism is reflected in the market, where a notable 9.00% of the company's float is held in short positions.

Market Sentiment & Smart Money

Short Interest %

9.00%

Analyst Consensus

1.33

Average Analyst Price Target

$9.00

Institutional Ownership %

65.80%

1-Year Beta

Insider Buying % (6 Mo)

Distance to 52-Week High

Distance to 52-Week Low

EARNINGS SURPRISE %

50-DAY SMA

200-DAY SMA

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.